Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),min,30,27657,DB00627,Niacin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,15,27658,DB00627,Niacin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,2,27659,DB00627,Niacin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,15.6,27660,DB00627,Niacin
,17431030,Urinary excretion,"Urinary excretion averaged 22% of the administered dose, for a total excretion recovery of approximately 90%.","Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431030/),%,22,49461,DB00627,Niacin
,17431030,total excretion recovery,"Urinary excretion averaged 22% of the administered dose, for a total excretion recovery of approximately 90%.","Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431030/),%,90,49462,DB00627,Niacin
,23347001,disappearance,"The mean IHN disappearance and NA appearance half-lives were 1.07 and 3.93 h in human plasma, and 0.152 and 2.68 h in rat plasma.",Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23347001/),h,1.07,64098,DB00627,Niacin
,23347001,disappearance,"The mean IHN disappearance and NA appearance half-lives were 1.07 and 3.93 h in human plasma, and 0.152 and 2.68 h in rat plasma.",Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23347001/),h,0.152,64099,DB00627,Niacin
,23347001,appearance half-lives,"The mean IHN disappearance and NA appearance half-lives were 1.07 and 3.93 h in human plasma, and 0.152 and 2.68 h in rat plasma.",Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23347001/),h,3.93,64100,DB00627,Niacin
,23347001,appearance half-lives,"The mean IHN disappearance and NA appearance half-lives were 1.07 and 3.93 h in human plasma, and 0.152 and 2.68 h in rat plasma.",Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23347001/),h,0.152,64101,DB00627,Niacin
,23347001,appearance half-lives,"The mean IHN disappearance and NA appearance half-lives were 1.07 and 3.93 h in human plasma, and 0.152 and 2.68 h in rat plasma.",Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23347001/),h,2.68,64102,DB00627,Niacin
,23347001,appearance half-life,"Increasing the initial plasma concentration to 50 µg/mL increased the NA appearance half-life in human and rat plasma to 4.66 and 6.47 h, respectively.",Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23347001/),h,4.66,64103,DB00627,Niacin
,23347001,appearance half-life,"Increasing the initial plasma concentration to 50 µg/mL increased the NA appearance half-life in human and rat plasma to 4.66 and 6.47 h, respectively.",Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23347001/),h,6.47,64104,DB00627,Niacin
,1958442,relative bioavailability,"3. The relative bioavailability of unchanged nicotinic acid from two slow release formulations compared with a rapid-release form was only 1% and 25%, respectively.",The bioavailability of sustained release nicotinic acid formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958442/),%,1,67177,DB00627,Niacin
,1958442,relative bioavailability,"3. The relative bioavailability of unchanged nicotinic acid from two slow release formulations compared with a rapid-release form was only 1% and 25%, respectively.",The bioavailability of sustained release nicotinic acid formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958442/),%,25,67178,DB00627,Niacin
,1958442,AUC (0.8 h),"Relative values of AUC (0.8 h) for nicotinuric acid were 15% and 58%, and relative urinary recoveries were 18% and 59%, respectively.",The bioavailability of sustained release nicotinic acid formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958442/),%,15,67179,DB00627,Niacin
,1958442,AUC (0.8 h),"Relative values of AUC (0.8 h) for nicotinuric acid were 15% and 58%, and relative urinary recoveries were 18% and 59%, respectively.",The bioavailability of sustained release nicotinic acid formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958442/),%,58,67180,DB00627,Niacin
,1958442,relative urinary recoveries,"Relative values of AUC (0.8 h) for nicotinuric acid were 15% and 58%, and relative urinary recoveries were 18% and 59%, respectively.",The bioavailability of sustained release nicotinic acid formulations. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958442/),%,18,67181,DB00627,Niacin
,1958442,relative urinary recoveries,"Relative values of AUC (0.8 h) for nicotinuric acid were 15% and 58%, and relative urinary recoveries were 18% and 59%, respectively.",The bioavailability of sustained release nicotinic acid formulations. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958442/),%,59,67182,DB00627,Niacin
,20853461,flow rate,"The chromatographic separation of NA, NAM, NUA, 2-Pyr and IS was achieved on a Hypersil-BDS column (150 x 4.6 mm, 5 microm) column using a mobile phase consisting of 0.1% formic acid : acetonitrile (20:80 v/v) at a flow rate of 1 mL/min.","Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853461/),[ml] / [min],1,80509,DB00627,Niacin
,20853461,total run time of analysis,"The total run time of analysis was 2 min and elution of NA, NAM, NUA, 2-Pyr and IS occurred at 1.37, 1.46, 1.40, 1.06 and 1.27 min, respectively.","Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853461/),min,2,80510,DB00627,Niacin
,20853461,elution,"The total run time of analysis was 2 min and elution of NA, NAM, NUA, 2-Pyr and IS occurred at 1.37, 1.46, 1.40, 1.06 and 1.27 min, respectively.","Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853461/),min,1.37,80511,DB00627,Niacin
,20853461,elution,"The total run time of analysis was 2 min and elution of NA, NAM, NUA, 2-Pyr and IS occurred at 1.37, 1.46, 1.40, 1.06 and 1.27 min, respectively.","Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853461/),min,1.46,80512,DB00627,Niacin
,20853461,elution,"The total run time of analysis was 2 min and elution of NA, NAM, NUA, 2-Pyr and IS occurred at 1.37, 1.46, 1.40, 1.06 and 1.27 min, respectively.","Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853461/),min,1.40,80513,DB00627,Niacin
,20853461,elution,"The total run time of analysis was 2 min and elution of NA, NAM, NUA, 2-Pyr and IS occurred at 1.37, 1.46, 1.40, 1.06 and 1.27 min, respectively.","Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853461/),min,1.06,80514,DB00627,Niacin
,20853461,elution,"The total run time of analysis was 2 min and elution of NA, NAM, NUA, 2-Pyr and IS occurred at 1.37, 1.46, 1.40, 1.06 and 1.27 min, respectively.","Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853461/),min,1.27,80515,DB00627,Niacin
,26345166,flow rate,"Following protein precipitation with acetonitrile, the NA, NUA, and internal standard (5-fluorouracil) were separated on a Zorbax 300SB-C8 column (250 mm × 4.6 mm, 5 μm) with a mobile phase consisting of methanol-2 mM ammonium acetate (3 : 97, v/v) at a flow rate of 1 mL/min (split 1 : 1).",Quantification of Niacin and Its Metabolite Nicotinuric Acid in Human Plasma by LC-MS/MS: Application to a Clinical Trial of a Fixed Dose Combination Tablet of Niacin Extended-Release/Simvastatin (500 mg/10 mg) in Healthy Chinese Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26345166/),[ml] / [min],1,86982,DB00627,Niacin
,20073472,maximum concentrations,"Trigonelline plasma levels increased from 160 nmol/L to maximum concentrations of 5479 (males) or 6547 nmol/L (females), and N-methylpyridinium plasma levels raised from virtually complete absence to maximum values of 777 (females) or 804 nmol/L (males) within 2-3 and 1-2 h after coffee consumption, respectively.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),[nM] / [l],5479,91138,DB00627,Niacin
,20073472,maximum concentrations,"Trigonelline plasma levels increased from 160 nmol/L to maximum concentrations of 5479 (males) or 6547 nmol/L (females), and N-methylpyridinium plasma levels raised from virtually complete absence to maximum values of 777 (females) or 804 nmol/L (males) within 2-3 and 1-2 h after coffee consumption, respectively.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),[nM] / [l],6547,91139,DB00627,Niacin
,20073472,maximum values,"Trigonelline plasma levels increased from 160 nmol/L to maximum concentrations of 5479 (males) or 6547 nmol/L (females), and N-methylpyridinium plasma levels raised from virtually complete absence to maximum values of 777 (females) or 804 nmol/L (males) within 2-3 and 1-2 h after coffee consumption, respectively.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),[nM] / [l],777,91140,DB00627,Niacin
,20073472,maximum values,"Trigonelline plasma levels increased from 160 nmol/L to maximum concentrations of 5479 (males) or 6547 nmol/L (females), and N-methylpyridinium plasma levels raised from virtually complete absence to maximum values of 777 (females) or 804 nmol/L (males) within 2-3 and 1-2 h after coffee consumption, respectively.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),[nM] / [l],804,91141,DB00627,Niacin
,20073472,urinary excretion,"Within 8 h after coffee intervention, an urinary excretion of 57.4 +/- 6.9% of trigonelline and 69.1 +/- 6.2% of N-methylpyridinium was found for the male volunteers, whereas females excreted slightly less with 46.2 +/- 7.4% and 61.9 +/- 12.2% of these pyridines.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),%,57.4,91142,DB00627,Niacin
,20073472,urinary excretion,"Within 8 h after coffee intervention, an urinary excretion of 57.4 +/- 6.9% of trigonelline and 69.1 +/- 6.2% of N-methylpyridinium was found for the male volunteers, whereas females excreted slightly less with 46.2 +/- 7.4% and 61.9 +/- 12.2% of these pyridines.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),%,69.1,91143,DB00627,Niacin
,20073472,urinary excretion,"Within 8 h after coffee intervention, an urinary excretion of 57.4 +/- 6.9% of trigonelline and 69.1 +/- 6.2% of N-methylpyridinium was found for the male volunteers, whereas females excreted slightly less with 46.2 +/- 7.4% and 61.9 +/- 12.2% of these pyridines.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),%,46.2,91144,DB00627,Niacin
,20073472,urinary excretion,"Within 8 h after coffee intervention, an urinary excretion of 57.4 +/- 6.9% of trigonelline and 69.1 +/- 6.2% of N-methylpyridinium was found for the male volunteers, whereas females excreted slightly less with 46.2 +/- 7.4% and 61.9 +/- 12.2% of these pyridines.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),%,61.9,91145,DB00627,Niacin
above,2609979,Recoveries,Recoveries of salicylic acid were found to be above 98.4% and the method was linear from 8-160 micrograms with a correlation coefficient of 0.9999.,[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),%,98.4,91918,DB00627,Niacin
,2609979,T1/2 (beta),"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),h,2.3374,91919,DB00627,Niacin
,2609979,T1/2 (beta),"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),h,0.9846,91920,DB00627,Niacin
,2609979,T1/2 (beta),"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),[h·μg] / [ml],157.71,91921,DB00627,Niacin
,2609979,AUC0-infinity,"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),[h·μg] / [ml],361.63,91922,DB00627,Niacin
,2609979,AUC0-infinity,"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),[h·μg] / [ml],157.71,91923,DB00627,Niacin
,21120461,C(max) (maximum plasma concentration) ratios,"The least-square mean between treatment C(max) (maximum plasma concentration) ratios (×100) were 97, 98, and 109% for ezetimibe, simvastatin and niacin, respectively.",Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21120461/),%,97,99614,DB00627,Niacin
,21120461,C(max) (maximum plasma concentration) ratios,"The least-square mean between treatment C(max) (maximum plasma concentration) ratios (×100) were 97, 98, and 109% for ezetimibe, simvastatin and niacin, respectively.",Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21120461/),%,98,99615,DB00627,Niacin
,21120461,C(max) (maximum plasma concentration) ratios,"The least-square mean between treatment C(max) (maximum plasma concentration) ratios (×100) were 97, 98, and 109% for ezetimibe, simvastatin and niacin, respectively.",Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21120461/),%,109,99616,DB00627,Niacin
,19489169,plasma half-life,"Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.",Development and pharmacology of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),min,30,100644,DB00627,Niacin
,19489169,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),%,40,100645,DB00627,Niacin
,19489169,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),%,60,100646,DB00627,Niacin
,19433974,apparent terminal half-life (t(1/2)),"The apparent terminal half-life (t(1/2)) was 26.0 and 14.8 hours for RIs and HSs, respectively (P = 0.007).",Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19433974/),h,26.0,102654,DB00627,Niacin
,19433974,apparent terminal half-life (t(1/2)),"The apparent terminal half-life (t(1/2)) was 26.0 and 14.8 hours for RIs and HSs, respectively (P = 0.007).",Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19433974/),h,14.8,102655,DB00627,Niacin
,19433974,apparent t(1/2),"Similarly, for the inactive laropiprant glucuronide metabolite, the GMR for AUC(0-infinity) was 2.17 (90% CI, 1.44-3.27), and the apparent t(1/2) values were 25.3 to 14.5 hours (P = 0.037) in RIs and HSs, respectively.",Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19433974/),h,25.3,102656,DB00627,Niacin
,19433974,apparent t(1/2),"Similarly, for the inactive laropiprant glucuronide metabolite, the GMR for AUC(0-infinity) was 2.17 (90% CI, 1.44-3.27), and the apparent t(1/2) values were 25.3 to 14.5 hours (P = 0.037) in RIs and HSs, respectively.",Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19433974/),h,14,102657,DB00627,Niacin
,17190374,AUC0-infinity,"After administering a single dose of each formulation, mean AUC0-infinity and Cmax values were 190.91+/-60.49 ng x h/ml and 3.87+/-1.04 ng/ml for the test formulation and 203.15+/-52.05 ng x h/ml and 4.01+/-0.60 ng/ml for the reference formulation, respectively.",Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190374/),[h·ng] / [ml],190.91,122461,DB00627,Niacin
,17190374,AUC0-infinity,"After administering a single dose of each formulation, mean AUC0-infinity and Cmax values were 190.91+/-60.49 ng x h/ml and 3.87+/-1.04 ng/ml for the test formulation and 203.15+/-52.05 ng x h/ml and 4.01+/-0.60 ng/ml for the reference formulation, respectively.",Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190374/),[h·ng] / [ml],203.15,122462,DB00627,Niacin
,17190374,Cmax,"After administering a single dose of each formulation, mean AUC0-infinity and Cmax values were 190.91+/-60.49 ng x h/ml and 3.87+/-1.04 ng/ml for the test formulation and 203.15+/-52.05 ng x h/ml and 4.01+/-0.60 ng/ml for the reference formulation, respectively.",Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190374/),[ng] / [ml],3.87,122463,DB00627,Niacin
,17190374,Cmax,"After administering a single dose of each formulation, mean AUC0-infinity and Cmax values were 190.91+/-60.49 ng x h/ml and 3.87+/-1.04 ng/ml for the test formulation and 203.15+/-52.05 ng x h/ml and 4.01+/-0.60 ng/ml for the reference formulation, respectively.",Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190374/),[ng] / [ml],4.01,122464,DB00627,Niacin
,18718822,flow rate,"A mobile phase of methanol-water containing 0.1% formic acid (50: 50, v/v) was used isocratically eluting at a flow rate of 1 mL/min.",Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of xanthinol in human plasma and its application in a bioequivalence study of xanthinol nicotinate tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18718822/),[ml] / [min],1,130617,DB00627,Niacin
,18718822,plasma extraction recovery,The mean plasma extraction recovery of xanthinol was in the range of 90.9-100.2%.,Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of xanthinol in human plasma and its application in a bioequivalence study of xanthinol nicotinate tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18718822/),%,90.9-100.2,130618,DB00627,Niacin
,18207467,flow rate,"Inositol hexanicotinate and the internal standard (mebendazole) were separated isocratically using a mobile phase of acetonitrile/phosphate buffer (35:65, v/v, pH 6.0) at a flow rate of 1.0mL/min and a reverse-phase XTerra MS C(18) column (4.6mmx150mm, 3.5microm).",Determination of inositol hexanicotinate in rat plasma by high performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18207467/),[ml] / [min],1.0,151164,DB00627,Niacin
,18207467,recovery,"At plasma concentrations of 1.5-100microg/mL, the mean recovery of inositol hexanicotinate was 99.6%.",Determination of inositol hexanicotinate in rat plasma by high performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18207467/),%,99.6,151165,DB00627,Niacin
,21417609,distribution volume,"Based on the plasma concentration profile, NEt-3IP (3-isopropoxy) was shown to have a distribution volume of 4.53 L/kg, and to be cleared from the body with an elimination half-time of 0.95 h.",Pharmacokinetic properties of newly synthesized retinoid X receptor agonists possessing a 6-[N-ethyl-N-(3-alkoxy-4-isopropylphenyl)amino]nicotinic acid skeleton in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417609/),[l] / [kg],4.53,151958,DB00627,Niacin
,21417609,elimination half-time,"Based on the plasma concentration profile, NEt-3IP (3-isopropoxy) was shown to have a distribution volume of 4.53 L/kg, and to be cleared from the body with an elimination half-time of 0.95 h.",Pharmacokinetic properties of newly synthesized retinoid X receptor agonists possessing a 6-[N-ethyl-N-(3-alkoxy-4-isopropylphenyl)amino]nicotinic acid skeleton in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417609/),h,0.95,151959,DB00627,Niacin
,21417609,bioavailability,"The bioavailability of NEt-3IP is 16.4%, whereas those of the isobutoxy analog NEt-3IB and the cyclopropylmethoxy analog NEt-3cPM are 46.5% and 22.6%, respectively.",Pharmacokinetic properties of newly synthesized retinoid X receptor agonists possessing a 6-[N-ethyl-N-(3-alkoxy-4-isopropylphenyl)amino]nicotinic acid skeleton in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417609/),%,16.4,151960,DB00627,Niacin
,21417609,bioavailability,"The bioavailability of NEt-3IP is 16.4%, whereas those of the isobutoxy analog NEt-3IB and the cyclopropylmethoxy analog NEt-3cPM are 46.5% and 22.6%, respectively.",Pharmacokinetic properties of newly synthesized retinoid X receptor agonists possessing a 6-[N-ethyl-N-(3-alkoxy-4-isopropylphenyl)amino]nicotinic acid skeleton in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417609/),%,46.5,151961,DB00627,Niacin
,21417609,bioavailability,"The bioavailability of NEt-3IP is 16.4%, whereas those of the isobutoxy analog NEt-3IB and the cyclopropylmethoxy analog NEt-3cPM are 46.5% and 22.6%, respectively.",Pharmacokinetic properties of newly synthesized retinoid X receptor agonists possessing a 6-[N-ethyl-N-(3-alkoxy-4-isopropylphenyl)amino]nicotinic acid skeleton in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417609/),%,22.6,151962,DB00627,Niacin
,21417609,K(m),"Subsequently, in the experiments using rat liver microsomes, the K(m) and V(max) values of NEt-3IP were determined as 7.85 µM and 0.48 nmol/min/mg protein, respectively.",Pharmacokinetic properties of newly synthesized retinoid X receptor agonists possessing a 6-[N-ethyl-N-(3-alkoxy-4-isopropylphenyl)amino]nicotinic acid skeleton in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417609/),μM,7.85,151963,DB00627,Niacin
,21417609,V(max),"Subsequently, in the experiments using rat liver microsomes, the K(m) and V(max) values of NEt-3IP were determined as 7.85 µM and 0.48 nmol/min/mg protein, respectively.",Pharmacokinetic properties of newly synthesized retinoid X receptor agonists possessing a 6-[N-ethyl-N-(3-alkoxy-4-isopropylphenyl)amino]nicotinic acid skeleton in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417609/),[nM] / [mg·min],0.48,151964,DB00627,Niacin
,21727043,m/,The protonated precursor to product ion transitions monitored for cycloserine and niacin were at m/z 103.1 → 75.0 and 124.1 → 80.1 respectively.,Development and validation of a selective and sensitive LC-MS/MS method for determination of cycloserine in human plasma: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21727043/),,103.1,153025,DB00627,Niacin
,21727043,m/,The protonated precursor to product ion transitions monitored for cycloserine and niacin were at m/z 103.1 → 75.0 and 124.1 → 80.1 respectively.,Development and validation of a selective and sensitive LC-MS/MS method for determination of cycloserine in human plasma: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21727043/),,75.0,153026,DB00627,Niacin
,21727043,m/,The protonated precursor to product ion transitions monitored for cycloserine and niacin were at m/z 103.1 → 75.0 and 124.1 → 80.1 respectively.,Development and validation of a selective and sensitive LC-MS/MS method for determination of cycloserine in human plasma: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21727043/),,124.1,153027,DB00627,Niacin
,21727043,m/,The protonated precursor to product ion transitions monitored for cycloserine and niacin were at m/z 103.1 → 75.0 and 124.1 → 80.1 respectively.,Development and validation of a selective and sensitive LC-MS/MS method for determination of cycloserine in human plasma: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21727043/),,80.1,153028,DB00627,Niacin
,21727043,limit of detection (LOD),The limit of detection (LOD) and lower limit of quantitation of the method were 0.0013 and 0.20 μg/mL respectively with a linear dynamic range of 0.20-30.00 μg/mL for cycloserine.,Development and validation of a selective and sensitive LC-MS/MS method for determination of cycloserine in human plasma: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21727043/),[μg] / [ml],0.0013,153029,DB00627,Niacin
,21727043,limit of detection (LOD),The limit of detection (LOD) and lower limit of quantitation of the method were 0.0013 and 0.20 μg/mL respectively with a linear dynamic range of 0.20-30.00 μg/mL for cycloserine.,Development and validation of a selective and sensitive LC-MS/MS method for determination of cycloserine in human plasma: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21727043/),[μg] / [ml],0.20,153030,DB00627,Niacin
,19369827,steady-state plasma levels,GMX1777 at a dose of 75 mg/kg administered over a 24 h intravenous infusion produced GMX1778 steady-state plasma levels of approximately 1 microg/ml and caused nicotinamide adenine dinucleotide levels to decrease significantly in tumors.,Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369827/),[μg] / [ml],1,159405,DB00627,Niacin
,20562093,t(max),"t(max) of NA were on average 0.75 h in dialysis patients and 3.0 h in CKD patients and, therefore, especially for dialysis patients, clearly shorter than expected for extended-release formulations.",Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20562093/),h,0.75,170185,DB00627,Niacin
,20562093,t(max),"t(max) of NA were on average 0.75 h in dialysis patients and 3.0 h in CKD patients and, therefore, especially for dialysis patients, clearly shorter than expected for extended-release formulations.",Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20562093/),h,3.0,170186,DB00627,Niacin
,24337137,run time of analysis,The run time of analysis was 5 min.,Development and validation of a LC-MS/MS method for D-cycloserine determination in human plasma for bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24337137/),min,5,193827,DB00627,Niacin
,24337137,relative recovery,"The mean relative recovery of cycloserine and niacin were 77.2 and 82.4 %, respectively.",Development and validation of a LC-MS/MS method for D-cycloserine determination in human plasma for bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24337137/),%,77.2,193828,DB00627,Niacin
,24337137,relative recovery,"The mean relative recovery of cycloserine and niacin were 77.2 and 82.4 %, respectively.",Development and validation of a LC-MS/MS method for D-cycloserine determination in human plasma for bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24337137/),%,82.4,193829,DB00627,Niacin
,4009437,terminal half-life,"Etofibrate, the ethylene glycol diester of clofibric and nicotinic acids, on intravenous infusion into dogs, has a terminal half-life of 2 min.","Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009437/),min,2,201105,DB00627,Niacin
,4009437,terminal half-lives,"The intermediate half-esters, the nicotinate and the clofibrate, have respective terminal half-lives of 4.6 and 1.7 min and appear fleetingly when etofibrate is administered.","Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009437/),min,4.6,201106,DB00627,Niacin
,4009437,terminal half-lives,"The intermediate half-esters, the nicotinate and the clofibrate, have respective terminal half-lives of 4.6 and 1.7 min and appear fleetingly when etofibrate is administered.","Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009437/),min,1.7,201107,DB00627,Niacin
,4009437,terminal half-life,"In contrast to the 42-h terminal half-life of clofibric acid, the other final transformation product, nicotinic acid, shows saturable or dose-dependent pharmacokinetics in dogs that conform to the Michaelis-Menten equation with a terminal half-life of 4.4 min at low concentrations (less than 6.9 microM/kg).","Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009437/),h,42,201108,DB00627,Niacin
,4009437,terminal half-life,"In contrast to the 42-h terminal half-life of clofibric acid, the other final transformation product, nicotinic acid, shows saturable or dose-dependent pharmacokinetics in dogs that conform to the Michaelis-Menten equation with a terminal half-life of 4.4 min at low concentrations (less than 6.9 microM/kg).","Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009437/),min,4.4,201109,DB00627,Niacin
,4009437,renal clearance,Nicotinic acid is excreted 30% unchanged into urine with a renal clearance of 70 mL/min in 27-kg dogs.,"Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009437/),[ml] / [min],70,201110,DB00627,Niacin
,17725178,Cmax,Mean niacin Cmax and AUC(0-t) values were 9.3 microg/ml and 26.2 microg x h/ml and were the highest of all analytes measured.,Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),[μg] / [ml],9.3,204715,DB00627,Niacin
,17725178,AUC(0-t),Mean niacin Cmax and AUC(0-t) values were 9.3 microg/ml and 26.2 microg x h/ml and were the highest of all analytes measured.,Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),[h·μg] / [ml],26.2,204716,DB00627,Niacin
,17725178,tmax,"Peak niacin and NUA levels occurred at 4.6 h (median) while tmax for NAM and NNO were 8.6 and 11.1 h, respectively.",Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),h,8.6,204717,DB00627,Niacin
,17725178,tmax,"Peak niacin and NUA levels occurred at 4.6 h (median) while tmax for NAM and NNO were 8.6 and 11.1 h, respectively.",Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),h,11.1,204718,DB00627,Niacin
,17725178,plasma terminal half-life,The mean plasma terminal half-life for niacin (0.9 h) and NUA (1.3 h) was shorter as compared to NAM (4.3 h).,Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),h,0.9,204719,DB00627,Niacin
,17725178,plasma terminal half-life,The mean plasma terminal half-life for niacin (0.9 h) and NUA (1.3 h) was shorter as compared to NAM (4.3 h).,Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),h,1.3,204720,DB00627,Niacin
,17725178,plasma terminal half-life,The mean plasma terminal half-life for niacin (0.9 h) and NUA (1.3 h) was shorter as compared to NAM (4.3 h).,Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),h,4.3,204721,DB00627,Niacin
,17725178,recovery,"The highest recovery was for 2PY (37.9%), followed by MNA (16.0%) and NUA (11.6%).",Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),%,37.9,204722,DB00627,Niacin
,17725178,recovery,"The highest recovery was for 2PY (37.9%), followed by MNA (16.0%) and NUA (11.6%).",Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),%,16.0,204723,DB00627,Niacin
,17725178,recovery,"The highest recovery was for 2PY (37.9%), followed by MNA (16.0%) and NUA (11.6%).",Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),%,11.6,204724,DB00627,Niacin
,17725178,half-lives,"Mean half-lives for 2PY and MNA calculated in urine were 12.6 and 12.8 h, respectively.",Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),h,12.6,204725,DB00627,Niacin
,17725178,half-lives,"Mean half-lives for 2PY and MNA calculated in urine were 12.6 and 12.8 h, respectively.",Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),h,12.8,204726,DB00627,Niacin
,17523054,Cl(p),"Following intravenous (i.v.) administration of MK-0524 to rats and dogs (1 and 5 mg/kg), the mean Cl(p) was approximately 2 and approximately 6 ml/min/kg, the T(1/2) was approximately 7 and approximately 13 h and the Vd(ss) was approximately 1 and approximately 5 L/kg, respectively.","The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523054/),[ml] / [kg·min],2,207648,DB00627,Niacin
,17523054,Cl(p),"Following intravenous (i.v.) administration of MK-0524 to rats and dogs (1 and 5 mg/kg), the mean Cl(p) was approximately 2 and approximately 6 ml/min/kg, the T(1/2) was approximately 7 and approximately 13 h and the Vd(ss) was approximately 1 and approximately 5 L/kg, respectively.","The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523054/),[ml] / [kg·min],6,207649,DB00627,Niacin
,17523054,T(1/2),"Following intravenous (i.v.) administration of MK-0524 to rats and dogs (1 and 5 mg/kg), the mean Cl(p) was approximately 2 and approximately 6 ml/min/kg, the T(1/2) was approximately 7 and approximately 13 h and the Vd(ss) was approximately 1 and approximately 5 L/kg, respectively.","The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523054/),h,7,207650,DB00627,Niacin
,17523054,T(1/2),"Following intravenous (i.v.) administration of MK-0524 to rats and dogs (1 and 5 mg/kg), the mean Cl(p) was approximately 2 and approximately 6 ml/min/kg, the T(1/2) was approximately 7 and approximately 13 h and the Vd(ss) was approximately 1 and approximately 5 L/kg, respectively.","The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523054/),h,13,207651,DB00627,Niacin
,17523054,Vd(ss),"Following intravenous (i.v.) administration of MK-0524 to rats and dogs (1 and 5 mg/kg), the mean Cl(p) was approximately 2 and approximately 6 ml/min/kg, the T(1/2) was approximately 7 and approximately 13 h and the Vd(ss) was approximately 1 and approximately 5 L/kg, respectively.","The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523054/),[l] / [kg],1,207652,DB00627,Niacin
,17523054,Vd(ss),"Following intravenous (i.v.) administration of MK-0524 to rats and dogs (1 and 5 mg/kg), the mean Cl(p) was approximately 2 and approximately 6 ml/min/kg, the T(1/2) was approximately 7 and approximately 13 h and the Vd(ss) was approximately 1 and approximately 5 L/kg, respectively.","The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523054/),[l] / [kg],5,207653,DB00627,Niacin
,17523054,C(max),"Following oral dosing of MK-0524 to rats (5, 25 and 100 mg/kg), dogs (5 mg/kg) and monkeys (3 mg/kg), the absorption was rapid with the mean C(max) occurring between 1 and 4 h.","The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523054/),h,1 and 4,207654,DB00627,Niacin
,17523054,Absolute oral bioavailability,"Absolute oral bioavailability values in rats, dogs and monkeys were 50, 70 and 8%, respectively.","The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523054/),%,50,207655,DB00627,Niacin
,17523054,Absolute oral bioavailability,"Absolute oral bioavailability values in rats, dogs and monkeys were 50, 70 and 8%, respectively.","The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523054/),%,70,207656,DB00627,Niacin
,17523054,Absolute oral bioavailability,"Absolute oral bioavailability values in rats, dogs and monkeys were 50, 70 and 8%, respectively.","The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523054/),%,8,207657,DB00627,Niacin
,24154936,Tmax,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,3.8,208386,DB00627,Niacin
,24154936,Tmax,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,3.9,208387,DB00627,Niacin
,24154936,Cmax,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],2 091,208388,DB00627,Niacin
,24154936,Cmax,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],2 323,208389,DB00627,Niacin
,24154936,AUC0-t,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],4 123.88,208390,DB00627,Niacin
,24154936,AUC0-t,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],4 385.98,208391,DB00627,Niacin
,24154936,Tmax,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,4.7,208392,DB00627,Niacin
,24154936,Tmax,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,3.8,208393,DB00627,Niacin
,24154936,Cmax,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],1 057,208394,DB00627,Niacin
,24154936,Cmax,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],1 087,208395,DB00627,Niacin
,24154936,AUC0-t,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],4 012.49,208396,DB00627,Niacin
,24154936,AUC0-t,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],4 040.45,208397,DB00627,Niacin
,24154936,Tmax,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,1.8,208398,DB00627,Niacin
,24154936,Tmax,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,2.5,208399,DB00627,Niacin
,24154936,Cmax,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],3.15,208400,DB00627,Niacin
,24154936,Cmax,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],4.87,208401,DB00627,Niacin
,24154936,AUC0-t,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],9.03,208402,DB00627,Niacin
,24154936,AUC0-t,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],17.63,208403,DB00627,Niacin
,24154936,Tmax,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,5.8,208404,DB00627,Niacin
,24154936,Tmax,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,6.5,208405,DB00627,Niacin
,24154936,Cmax,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],4.22,208406,DB00627,Niacin
,24154936,Cmax,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],9.30,208407,DB00627,Niacin
,24154936,AUC0-t,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],34.65,208408,DB00627,Niacin
,24154936,AUC0-t,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],61.62,208409,DB00627,Niacin
,24154936,Urine Recovery rate,Urine Recovery rate of total niacin: (40.55±7.38)% and (62.87±12.04)%.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),%,40.55,208410,DB00627,Niacin
,24154936,Urine Recovery rate,Urine Recovery rate of total niacin: (40.55±7.38)% and (62.87±12.04)%.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),%,62.87,208411,DB00627,Niacin
,9278201,areas under the pruritus intensity-time curve,"The areas under the pruritus intensity-time curve were promethazine 105 +/- 28 (units h), niacin 76 +/- 22, prednisolone 28 +/- 24, and prednisolone and niacin 34 +/- 17 (P < 0.001 ANOVA).","Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278201/),h·units,105,209541,DB00627,Niacin
,9278201,areas under the pruritus intensity-time curve,"The areas under the pruritus intensity-time curve were promethazine 105 +/- 28 (units h), niacin 76 +/- 22, prednisolone 28 +/- 24, and prednisolone and niacin 34 +/- 17 (P < 0.001 ANOVA).","Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278201/),h·units,76,209542,DB00627,Niacin
,9278201,areas under the pruritus intensity-time curve,"The areas under the pruritus intensity-time curve were promethazine 105 +/- 28 (units h), niacin 76 +/- 22, prednisolone 28 +/- 24, and prednisolone and niacin 34 +/- 17 (P < 0.001 ANOVA).","Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278201/),h·units,28,209543,DB00627,Niacin
,9278201,areas under the pruritus intensity-time curve,"The areas under the pruritus intensity-time curve were promethazine 105 +/- 28 (units h), niacin 76 +/- 22, prednisolone 28 +/- 24, and prednisolone and niacin 34 +/- 17 (P < 0.001 ANOVA).","Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278201/),h·units,34,209544,DB00627,Niacin
,4039571,peak whole blood levels,"Mean peak whole blood levels of 11.9 micrograms/ml at 2.8 h and 35.3 micrograms/ml at 1.3 h, respectively, occurred after administration of etofibrate and nicotinic acid alone.",Bioavailability studies of etofibrate in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039571/),[μg] / [ml],11.9,212497,DB00627,Niacin
,4039571,peak whole blood levels,"Mean peak whole blood levels of 11.9 micrograms/ml at 2.8 h and 35.3 micrograms/ml at 1.3 h, respectively, occurred after administration of etofibrate and nicotinic acid alone.",Bioavailability studies of etofibrate in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039571/),[μg] / [ml],35.3,212498,DB00627,Niacin
,4039571,peak plasma levels,"However, mean peak plasma levels of 127.3 micrograms/ml at 3.6 h and 170.8 micrograms/ml at 2.4 h, respectively, occurred after administration of etofibrate and clofibric acid alone and were significantly different (P less than 0.01).",Bioavailability studies of etofibrate in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039571/),[μg] / [ml],127.3,212499,DB00627,Niacin
,4039571,peak plasma levels,"However, mean peak plasma levels of 127.3 micrograms/ml at 3.6 h and 170.8 micrograms/ml at 2.4 h, respectively, occurred after administration of etofibrate and clofibric acid alone and were significantly different (P less than 0.01).",Bioavailability studies of etofibrate in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039571/),[μg] / [ml],170.8,212500,DB00627,Niacin
,4039571,half-lives,"The half-lives of nicotinic acid (in whole blood) and clofibric acid (in plasma) in rhesus monkeys when these drugs were administered alone were 9.9 h and 1.8 h, respectively.",Bioavailability studies of etofibrate in rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039571/),h,9.9,212501,DB00627,Niacin
,4039571,half-lives,"The half-lives of nicotinic acid (in whole blood) and clofibric acid (in plasma) in rhesus monkeys when these drugs were administered alone were 9.9 h and 1.8 h, respectively.",Bioavailability studies of etofibrate in rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039571/),h,1.8,212502,DB00627,Niacin
,22415894,flow rate,"The chromatographic separation was achieved on a Hypurity Advance (4.6 × 50 mm, 5 µm) column using a mobile phase consisting of 0.1% formic acid buffer-acetonitrile (20:80, v/v) at flow rate of 0.8 mL/min.",Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22415894/),[ml] / [min],0.8,212745,DB00627,Niacin
,22415894,total run time of analysis,"The total run time of analysis was 3 min and elution of AT, NA and IS occurred at 1.06, 1.84 and 0.92 min, respectively.",Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22415894/),min,3,212746,DB00627,Niacin
,22326030,T(max),"ST0702 is metabolised in vivo to aspirin, niacin and salicylic acid with T(max) values of 30, 45 and 95 min respectively using a non-compartmental model.",In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22326030/),min,30,229859,DB00627,Niacin
,22326030,T(max),"ST0702 is metabolised in vivo to aspirin, niacin and salicylic acid with T(max) values of 30, 45 and 95 min respectively using a non-compartmental model.",In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22326030/),min,45,229860,DB00627,Niacin
,22326030,T(max),"ST0702 is metabolised in vivo to aspirin, niacin and salicylic acid with T(max) values of 30, 45 and 95 min respectively using a non-compartmental model.",In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22326030/),min,95,229861,DB00627,Niacin
,8297546,plasma half-life,"Systemic exposure is limited because of extensive sequestration by the liver and/or first-pass metabolism, a plasma half-life of approximately 30 min, no circulating active metabolites, and no accumulation of drug during chronic dosing.",Pharmacokinetics of fluvastatin and specific drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8297546/),min,30,232734,DB00627,Niacin
,21915888,flow rate,"Separation of SV, LV, NIA and the IS was achieved on an Alltima C₁₈ column with a mobile phase consisting of 5 mm ammonium acetate (pH 4.5) and acetonitrile (20:80, v/v) pumped at a flow rate of 1 mL/min.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),[ml] / [min],1,233942,DB00627,Niacin
,21915888,Nominal retention times,"Nominal retention times obtained for SV, LV, NIA and IS were 2.12, 1.67, 0.50 and 0.65 min, respectively.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),min,2.12,233943,DB00627,Niacin
,21915888,Nominal retention times,"Nominal retention times obtained for SV, LV, NIA and IS were 2.12, 1.67, 0.50 and 0.65 min, respectively.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),min,1.67,233944,DB00627,Niacin
,21915888,Nominal retention times,"Nominal retention times obtained for SV, LV, NIA and IS were 2.12, 1.67, 0.50 and 0.65 min, respectively.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),min,0.50,233945,DB00627,Niacin
,21915888,Nominal retention times,"Nominal retention times obtained for SV, LV, NIA and IS were 2.12, 1.67, 0.50 and 0.65 min, respectively.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),min,0.65,233946,DB00627,Niacin
,23934776,m,Multiple reaction monitoring (m/z 353.9 → 148.6 for N2L and m/z 356.0 → 192.0 for internal standard) was performed for detection and quantification.,"Determination of newly synthesized lipoic acid-niacin dimer in rat plasma by UPLC/electrospray ionization tandem mass spectrometry: assay development, validation and application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23934776/),,148.6,234454,DB00627,Niacin
,23934776,m,Multiple reaction monitoring (m/z 353.9 → 148.6 for N2L and m/z 356.0 → 192.0 for internal standard) was performed for detection and quantification.,"Determination of newly synthesized lipoic acid-niacin dimer in rat plasma by UPLC/electrospray ionization tandem mass spectrometry: assay development, validation and application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23934776/),,192.0,234455,DB00627,Niacin
,11318787,AUC,The administration of A induced a FFA reduction during the entire test both when administered with placebo and with GHRH: AUC (mmol/l x 90 minutes): placebo plus placebo: 88.2 +/- 7.3.,Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318787/),[mM] / [90·l·min],88.2,255278,DB00627,Niacin
,11318787,peak GH level,Mean peak GH level (microg/l) after placebo plus placebo was 5.0 +/- 1.8 not significantly different than after placebo plus A with a mean peak of 6.2 +/- 2 (P = ns).,Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318787/),[μg] / [l],5.0,255279,DB00627,Niacin
,11318787,peak,Mean peak GH level (microg/l) after placebo plus placebo was 5.0 +/- 1.8 not significantly different than after placebo plus A with a mean peak of 6.2 +/- 2 (P = ns).,Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318787/),,6.2,255280,DB00627,Niacin
,11318787,peak,Mean peak GHRH-induced GH secretion was 26.0 +/- 15.4 and was not modified by previous A administration with mean peak of 24.4 +/- 11.8 (P = ns).,Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318787/),,26.0,255281,DB00627,Niacin
,11318787,peak,Mean peak GHRH-induced GH secretion was 26.0 +/- 15.4 and was not modified by previous A administration with mean peak of 24.4 +/- 11.8 (P = ns).,Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318787/),,24.4,255282,DB00627,Niacin
,8729584,plasma half-life,"Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.",Development and pharmacology of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),min,30,257876,DB00627,Niacin
,8729584,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),%,40,257877,DB00627,Niacin
,8729584,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),%,60,257878,DB00627,Niacin
,7874071,pKa,"Judging from their pKa values (5.68 and 5.91 for VADPH and VPDPH, respectively) and pH-solubilities, VADPH and VPDPH were acidic compounds, while MNDPH was basic.",Physicochemical and hydrolytic characteristics of phenytoin derivatives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874071/),,5.68,258918,DB00627,Niacin
,7874071,pKa,"Judging from their pKa values (5.68 and 5.91 for VADPH and VPDPH, respectively) and pH-solubilities, VADPH and VPDPH were acidic compounds, while MNDPH was basic.",Physicochemical and hydrolytic characteristics of phenytoin derivatives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874071/),,5.91,258919,DB00627,Niacin
,21466853,half-life,"Using the Arrhenius equation, the extrapolated half-life at 37°C were 289 days at pH 1.2 for the codrug and 130 and 20,315 days at pH 6.8 for the codrug and gemfibrozil 2-hydroxyethyl ester (GHEE), respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),d,289,264658,DB00627,Niacin
,21466853,half-life,"Using the Arrhenius equation, the extrapolated half-life at 37°C were 289 days at pH 1.2 for the codrug and 130 and 20,315 days at pH 6.8 for the codrug and gemfibrozil 2-hydroxyethyl ester (GHEE), respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),d,130,264659,DB00627,Niacin
,21466853,half-life,"Using the Arrhenius equation, the extrapolated half-life at 37°C were 289 days at pH 1.2 for the codrug and 130 and 20,315 days at pH 6.8 for the codrug and gemfibrozil 2-hydroxyethyl ester (GHEE), respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),d,"20,315",264660,DB00627,Niacin
,21466853,half-lives,"The shortest half-lives were at pH 7.4; 42 days for the codrug and 5837 days for GHEE, respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),d,42,264661,DB00627,Niacin
,21466853,half-lives,"The shortest half-lives were at pH 7.4; 42 days for the codrug and 5837 days for GHEE, respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),d,5837,264662,DB00627,Niacin
,21466853,k(obs),The k(obs) was found in both cases to be 1.60×10(-3)h(-1).,"Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),1/[h],1.60×10(-3),264663,DB00627,Niacin
,21466853,half-lives,"The half-lives in plasma were 35.24 min and 26.75 h for the codrug and GHEE, respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),min,35.24,264664,DB00627,Niacin
,21466853,half-lives,"The half-lives in plasma were 35.24 min and 26.75 h for the codrug and GHEE, respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),h,26.75,264665,DB00627,Niacin
,21466853,hydrolysis half-lives,"With regard to liver homogenate, the hydrolysis half-lives were 1.96 min and 48.13 min for the codrug and GHEE, respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),min,1.96,264666,DB00627,Niacin
,21466853,hydrolysis half-lives,"With regard to liver homogenate, the hydrolysis half-lives were 1.96 min and 48.13 min for the codrug and GHEE, respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),min,48.13,264667,DB00627,Niacin
